As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -22 -22 |
22%
22%
|
|
| EBIT (Operating Income) EBIT | -24 -24 |
19%
19%
|
|
| Net Profit | -34 -34 |
43%
43%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. Its technologies include Intelligent Immunotherapy, Diamond AI, CancerSplice, ABBIE, and CAR-T Proprietary Binder Technology. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.
| Head office | United States |
| CEO | Pietro Bersani |
| Employees | 44 |
| Founded | 2006 |
| Website | kiromic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


